Pharmaceutical manufacturers of Verapamil

Sicor, situated in the northern region of Italy, is a component of the Teva API business and offers a worldwide platform for the production and promotion of APIs for injectable, inhalation, topical, and nasal products. These specialized facilities possess a significant level of skill, manufacturing approximately 60 active pharmaceutical ingredients.

Piramal Group has interests in a portfolio of businesses including financial services (Piramal Enterprises Limited), pharmaceuticals (Piramal Pharma Limited), and real estate (Piramal Realty). With operations in 30 countries and brand presence in over 100 markets, the Group’s turnover is ~$1.9 billion in FY 2022. Driven by its core values, the Group pursues inclusive growth, while adhering to ethical and value-driven practices. Piramal Foundation has initiatives in primary healthcare, nutrition, water, and social sector ecosystems.

Cadila Pharmaceuticals Ltd. is one of the largest privately-held pharmaceutical companies in India. Over the past seven decades, we have been developing and manufacturing affordable medicines for patients around the world. Our innovation-led drug discovery processes ensure the health and well-being of people around the world. Our enhanced investment in innovation and a strong track record in research and development have produced medical miracles that have changed lives and made a profound impact on real life.

VIATRIS™ represents a fresh approach to healthcare, dedicated to ensuring medicine accessibility, promoting sustainable practices, pioneering creative remedies, and enhancing patient results. Founded in 2020 through the merger of Mylan and Upjohn, Viatris unites top-notch scientific, production and distribution skills with established regulatory, medical and commercial proficiencies.

The Ajinomoto Group has advanced its purpose from “Unlocking the power of amino acids to resolve the food and health issues” to “contributing to the well-being of all human beings, our society and our planet with ‘AminoScience’.” We consider well-being to mean health and happiness. Our advanced purpose therefore represents our commitment to achieving two outcomes by 2030 which are connected by food systems: to reduce our environmental impact by 50% and to help extend the healthy life expectancy of 1 billion people.

From removing the regular pain of fingersticks as people manage their diabetes to connecting patients to doctors with real-time information monitoring their hearts, from easing chronic pain and movement disorders to testing half the world’s blood donations to ensure a healthy supply, our purpose is to make the world a better place by bringing life-changing health technologies to the people who need them. That’s our commitment to helping you live your best life.

Aurore Life Sciences is a specialized manufacturer of active pharmaceutical ingredients (API) with a varied range of capabilities to enhance efficiency for generic pharmaceutical companies worldwide. Established in 2017 by a team with extensive expertise throughout the pharmaceutical supply chain, the company is dedicated to becoming the most favored partner for pharmaceuticals. At Aurore, we strive to innovate in the production and delivery of dependable high-quality products, earning the trust of both customers and regulatory bodies. Our focus on rapidly expanding capabilities has driven us to acquire, integrate, and extend our presence across multiple regions.

Recordati, an Italian pharmaceutical company, is publicly traded on the Italian Stock Exchange. Its unique structure allows it to provide healthcare solutions in various areas including specialty and primary care, consumer healthcare, and rare diseases. With a history dating back to 1926, Recordati has a presence in around 150 countries spanning the EMEA, Americas, and APAC regions.

Dasami Lab Private Limited was officially established through MCA on the 24th of July 2015. Categorized as a private limited company, it falls under the classification of Non Government Company. The company is registered at Registrar of Companies(ROC) in Hyderabad, with an Authorized Share Capital of Rs. 110 CR and a paid up capital of 110 CR.

Cohance Lifesciences stands as a prominent CDMO and API platform, providing a wide range of products and services throughout every stage of a compound's lifespan, from its development to commercialization. Leveraging our expertise in intricate chemical processes, we deliver comprehensive CDMO services to global innovators and have successfully overseen numerous projects from inception to market launch over the years. As a global API participant, we cater to clients in approximately 60 nations, offering 80+ molecules supported by strong research and development, regulatory capabilities, and manufacturing facilities. Committed to excellence, we are one of the leading integrated exporters of pellets and possess formidable development and manufacturing capabilities.

Orofino Pharmaceuticals Group (OPG) comprises a variety of specialized companies offering third-party manufacturing services, all FDA approved. They are dedicated to providing high-quality services to customers at a competitive cost, with a focus on enhancing the technical quality of productions and the sterile administration of injectable products. OPG is actively engaged in the development of new pharmaceutical products and holds several strategic new patents.

Assurgen pharma strongly holds the belief that, with its expertise and innovative background in the pharmaceutical business, it is well positioned for manufacturing APIs & Intermediates and outsourcing for the global market. The company also engages in custom synthesis and contract manufacturing. Ongoing significant investment ensures a consistent supply of high-quality products and world-class service. Assurgen Pharma is known for being flexible, efficient, cost-effective, and responsive to customers' needs. The primary quality policy is to strive for the highest levels of customer satisfaction, with a focus on manufacturing drugs that meet the highest GMP standards.

Drug’On Pharma Switzerland is the most recent addition to the Orofino Pharmaceuticals Group, having acquired the former Knoll and Abbott manufacturing site in Liestal, Switzerland. The facility specializes in the production of active pharmaceuticals ingredients (API) and intermediates, as well as managing Technology Transfer. Notably, the site has established significant joint ventures with leading chemical companies. It is accredited by RHI-Swissmedic, EU-GMP, FDA, and Japan PMDA, and comprises four distinct chemical manufacturing buildings staffed by highly specialized employees.